Share Information

Please click the link below to the London Stock Exchange to receive the actual share price information and/or a free annual report.

Investor relations contact

Powerscourt: Paul Durman, Kay Larsen
E-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
E-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Phone: + 44 20 7250 1446

Vida Communication: Tim Brons, Stepahnie Diaz
E-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
E-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Phone: + 1 415 675 7400

Registrars

For enquiriesabout shareholding or share registration, please contact the Group’s Registrars:

Capita IRG plc, The Registry, 34 Beckenham Road, Beckenham,Kent, BR3 4TU.
Tel: 020 8639 3399 Fax:020 8639 2342 Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Shareholders Rights

Summary of Articles

Memorandum of Association

Full Articles of Association

Document Last Updated ( Friday, 15 January 2010 )

Contact Legal Disclaimer Company Info © Silence Therapeutics 2007

Transmenu powered by JoomlArt.com - Mambo Joomla Professional Templates Club

In Brief

8 February 2010 Silence Therapeutics Receives Notice of Allowance for RNAi Patent Covering Novel Cancer Target
Read more...

5 February 2010 Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Read more...

5 January 2010 Silence and Intradigm complete merger to form a leading company in the field of RNAi
Read more...

4 January 2010 Shareholders pass all resolutions at EGM
Read more...

16 December 2009 Silence Therapeutics to merge with Intradigm Corp to create leading RNAi therapeutics company
Read more...

16 December 2009
Admission Document – Circular to Shareholders in full
download Admission Document

14 December 2009 Shareholders pass all resolutions at AGM
Read more...

15 October 2009 Silence Therapeutics’ core patent upheld
Read more...

30 September 2009 Silence announces Interim Results for the six months ended 30 June 2009
Read more...

29 September 2009 Silence announces temporary suspension of shares pending outcome of M&A talks
Read more...

17 September 2009 Silence will release its interim results for the 6 months to 30 June 2009 on 30 September 2009
Read more...

27 August 2009 Silence Therapeutics signs siRNA delivery collaboration with Dainippon Sumitomo Pharma
Read more...

23 June 2009 Silence announces dosing of first patient in Atu027 cancer trial
Read more...

3 June 2009 Silence receives approval to commence Phase I clinical trial with Atu027
Read more...

21 January 2009 Successful oppostion to 2^nd EP on Keutzer-Limmer
Read more...

9 January 2009 EPO grants Silence Therapeutics’ Patent
Read more...